Intertek is the industry leader with over 42,000 people in 1,000 locations in over 100 countries. Whether your business is local or global, we can ensure your products meet quality, health, environmental, safety, and social accountability standards for virtually any market around the world.
Intertek to run a workshop on inhalation product characterization studies at RDD Asia 2016
Intertek experts will train industry professionals on strategic approaches to inhalation product characterisation within RDD Asia workshop on November 9th
Orally inhaled or nasal drug products (OINDP) require detailed product characterization studies which include chemical analysis, physicochemical property testing, performance testing and stability studies to support a successful regulatory submission.
During the forthcoming RDD Asia 2016 conference, our inhalation experts Mark Parry, Technical Director, and Chris Vernall, Business Development Manager, will be present to deliver training as part of the Interactive Workshop Sessions. They will also be available to provide updates on the latest developments in our inhaled product development capabilities for nasal sprays, dry powder inhalers (DPIs), metered dose inhalers (MDIs) and nebulisers.
Our integrated formulation and analytical teams carry out early stage pre-formulation support, solubility screening, drug-excipient compatibility, stability testing and device selection support to aid clients working to develop formulations targeting specific regions of the respiratory tract or nasal cavity. Comprehensive protein characterisation services, aligned to monitoring a protein’s structure and potency throughout formulation and storage can also be provided.
Intertek RDD Asia Workshop:
Product Characterization Studies: What are they, why are they done, and what is involved?
Date: November 9th 2016, 2pm – 5pm
Specific documentation is required before any regulatory body will authorize any medical products for marketing. Key documents include the summary of products characterization (SmPC) and the patient information leaflet (PIL). Our experts will walk the participants through these key product characterization studies all the way from chemical, physicochemical, and performance testing to stability dossiers allowing for successful regulatory submission of OINDPs.
RDD Asia offers attendees the opportunity to participate in one of the largest and most focussed international conferences on respiratory drug delivery in Asia. It will feature industry updates, in-depth presentations and discussion of pioneering respiratory drug delivery science relating to pMDIs, DPIs, nebulizers, nasal sprays and emerging aerosol delivery platforms.
Expert speakers will cover topics including new therapeutic opportunities and drug delivery technologies, novel in vitro clinical testing methods and new regulatory insight during the conference program or workshop sessions.